Trial SWOG-S1117

A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Type: Cancer Therapy
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunomodulator
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Casey O Connell, M.D.
Other Trial Staff: Ibrahim Syed, D.M., Teh-Chun Wang, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at SWOG.org

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.